ReviewMolecular and clinical oncology2026
Tertiary lymphoid structure can be a potential therapeutic target for head and neck squamous cell carcinoma (Review).
Review in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tertiary lymphoid structure (TLS) is a kind of ectopic lymphoid tissues that form in chronic inflammation or tumor microenvironment (TME) and is structurally similar to secondary lymphoid organs such as lymph nodes, containing B cell follicles, T cell regions, and mature dendritic cells. It was reported that TLS is associated with improved prognosis and higher response rates to immunotherapy in a variety of tumors. However, the mechanism of TLS and its clinical significance in head and neck squamous cell carcinoma (HNSCC) remains unclear. In the present study, the latest advances of biological characteristics, research progress of TLS and its role in the TME were summarized. The relationship between the prognosis and response to immunotherapy of distinct cancers and the location, density and maturity of TLS were addressed. Predictive, therapeutic and prognostic values of TLS in HNSCC were also reviewed. In addition, the therapeutic value of TLS and the potential strategies for patients with HNSCC by regulating TLS were also discussed. Collectively, TLS can be regarded as an independent predictive biomarker for immunotherapy in HNSCC and appears to have a close correlation with the prognosis of HNSCC. Despite little acknowledge of mechanisms and few preclinical/clinical trials on TLS-targeted therapy, TLS-based therapy can provide a new potential therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.